<code id='B4756ECD15'></code><style id='B4756ECD15'></style>
    • <acronym id='B4756ECD15'></acronym>
      <center id='B4756ECD15'><center id='B4756ECD15'><tfoot id='B4756ECD15'></tfoot></center><abbr id='B4756ECD15'><dir id='B4756ECD15'><tfoot id='B4756ECD15'></tfoot><noframes id='B4756ECD15'>

    • <optgroup id='B4756ECD15'><strike id='B4756ECD15'><sup id='B4756ECD15'></sup></strike><code id='B4756ECD15'></code></optgroup>
        1. <b id='B4756ECD15'><label id='B4756ECD15'><select id='B4756ECD15'><dt id='B4756ECD15'><span id='B4756ECD15'></span></dt></select></label></b><u id='B4756ECD15'></u>
          <i id='B4756ECD15'><strike id='B4756ECD15'><tt id='B4756ECD15'><pre id='B4756ECD15'></pre></tt></strike></i>

          Home / fashion / focus

          focus


          focus

          author:explore    Page View:4965
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In